ARCHIVES

FDA cancer therapeutics review split among three units in reorganization.

This article is from The Cancer Letter archive.

Vol. 29 No. 37 | October 10, 2003

Download PDF Visit The Full Archive

Related Articles

Researcher Falsified EMF Data, ORI Says

July 30, 1999

Ohio State Schedules Workshop On CCOP

February 5, 1982

Adding Velcade Increased Overall Survival By 13.3 Months at Five-Year Analysis

December 30, 2011

How Much Is Life Worth? The $440 Billion Question

July 31, 2009

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

Genentech Says Phase III Trial Shows Avastin Improved PFS For Ovarian Cancer

March 26, 2010